Medifast Inc. (NYSE: MED) has reported a loss for its second fiscal quarter (ending June 30) of $-0.75 versus $2.78 for the same period a year ago — a decline of -127%. This result fell short of the consensus estimate of $0.39 by $-1.14. For the latest four quarters through June 30, E.P.S. were $2.68 versus $12.19 for the same period a year ago — a decline of -78%.
Recent Price Action
On 8/5/24, Medifast Inc. (NYSE: MED) stock declined by -2.8%, closing at $20.86. However, below average trading volume at 76% of normal accompanied the decline. Relative to the market the stock has been extremely weak over the last nine months but has risen 1.8% during the last week.
Current PriceTarget Research Rating
MED’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Medifast has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Medifast has a neutral Appreciation Score of 42 but a very low Power Rating of 5, and the Lowest Value Trend Rating results.
Rating Review
In light of this discouraging new earnings information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment